Compare LVWR & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LVWR | CRMD |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 977.1M | 943.9M |
| IPO Year | N/A | 2010 |
| Metric | LVWR | CRMD |
|---|---|---|
| Price | $4.58 | $12.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 60.3K | ★ 2.6M |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | $25,078,000.00 | ★ $214,303,672.00 |
| Revenue This Year | $249.13 | $627.89 |
| Revenue Next Year | $98.53 | $40.95 |
| P/E Ratio | ★ N/A | $5.56 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $0.93 | $5.60 |
| 52 Week High | $9.04 | $17.43 |
| Indicator | LVWR | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.22 | 66.86 |
| Support Level | $4.45 | $11.78 |
| Resistance Level | $4.96 | $12.51 |
| Average True Range (ATR) | 0.29 | 0.52 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 49.51 | 96.68 |
LiveWire Group Inc is an all-electric vehicle company. It sells electric vehicles and related parts and accessories and apparel in the United States and certain international markets. The company's segment includes Electric Motorcycles and STACYC. Electric Motorcycles segment sells electric motorcycles, related parts and accessories and apparel in the United States and certain international markets; STACYC segment sells electric balance bikes for kids, related parts and accessories and apparel in the United States and certain international markets. LiveWire generates revenue from the sale of electric motorcycles, Parts, accessories and apparel. Majority of revenue is from USA.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.